Volume 26, Issue 5, Pages (May 2018)

Slides:



Advertisements
Similar presentations
Volume 50, Issue 3, Pages (March 2009)
Advertisements

Volume 15, Issue 3, Pages (March 2007)
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
Molecular Therapy - Nucleic Acids
Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry Disease  Youichi Tajima, Ikuo Kawashima, Takahiro.
Volume 10, Issue 2, Pages (August 2009)
Volume 69, Issue 6, Pages (March 2006)
Volume 31, Issue 1, Pages (July 2009)
Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice  Lodewijk J.A. Toonen, Frank Rigo, Haico.
Volume 7, Issue 3, Pages (May 2014)
Volume 26, Issue 4, Pages (April 2018)
Arctigenin inhibits prostate tumor cell growth in vitro and in vivo
Molecular Therapy - Nucleic Acids
The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis  Yosuke Kanno, En Shu,
Volume 16, Issue 1, Pages (January 2008)
Volume 25, Issue 7, Pages (July 2017)
Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy  Ingo Roehl, Stephan Seiffert, Celia Brikh, Jonathan.
Volume 24, Issue 2, Pages (February 2016)
Volume 18, Issue 5, Pages (May 2010)
Volume 9, Issue 3, Pages (March 2004)
Volume 22, Issue 12, Pages (December 2014)
Diagnostic and Therapeutic Evaluation of an Anti-Langerhans Cell Histiocytosis Monoclonal Antibody (NA1/34) in a New Xenograft Model  Samuel Murray, Jenny.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 7, Pages (July 2014)
Volume 13, Issue 4, Pages (April 2006)
Volume 7, Issue 6, Pages (June 2014)
Daniel F. Wallace, Lesa Summerville, V. Nathan Subramaniam 
Volume 22, Issue 1, Pages (July 2012)
Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes  Shunsuke Iizuka, Fuminori Sakurai,
Volume 25, Issue 1, Pages (January 2017)
Volume 26, Issue 8, Pages (August 2018)
Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I  Cristina Martin-Higueras,
Volume 9, Issue 6, Pages (June 2004)
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 5, Pages (May 2014)
Volume 20, Issue 2, Pages (February 2013)
Volume 19, Issue 10, Pages (October 2011)
Molecular Therapy - Methods & Clinical Development
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Volume 25, Issue 7, Pages (July 2017)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 7, Pages (July 2017)
Volume 64, Issue 5, Pages (December 2009)
Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of niemann–pick.
The Effect of Size and Shape of RNA Nanoparticles on Biodistribution
LncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy  Juan Wang, Jian Pang, Huiling Li, Jie Long, Fang Fang, Junxiang Chen,
Volume 85, Issue 1, Pages (January 2014)
Volume 19, Issue 6, Pages (June 2011)
Volume 22, Issue 1, Pages (July 2012)
Hong Du, Mark Levine, Chandrashekar Ganesa, David P. Witte, Edward S
Kasey L Jackson, Robert D Dayton, Ronald L Klein 
Volume 26, Issue 1, Pages (January 2018)
Volume 3, Issue 3, Pages (March 2001)
Molecular Therapy - Nucleic Acids
Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice  Haiyan Fu, Kim Zaraspe, Naoko.
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Volume 25, Issue 4, Pages (April 2017)
Volume 27, Issue 1, Pages (January 2019)
Volume 16, Issue 4, Pages (April 2008)
Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis  Yu Sakurai, Tomoya.
Volume 46, Issue 5, Pages (June 2012)
Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer  Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,
Volume 25, Issue 2, Pages (February 2017)
Molecular Therapy - Methods & Clinical Development
Volume 16, Issue 4, Pages (April 2008)
Volume 23, Issue 12, Pages (June 2018)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Volume 11, Issue 6, Pages (June 2012)
Presentation transcript:

Volume 26, Issue 5, Pages 1366-1374 (May 2018) A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II  Hiroyuki Sonoda, Hideto Morimoto, Eiji Yoden, Yuri Koshimura, Masafumi Kinoshita, Galina Golovina, Haruna Takagi, Ryuji Yamamoto, Kohtaro Minami, Akira Mizoguchi, Katsuhiko Tachibana, Tohru Hirato, Kenichi Takahashi  Molecular Therapy  Volume 26, Issue 5, Pages 1366-1374 (May 2018) DOI: 10.1016/j.ymthe.2018.02.032 Copyright © 2018 The Author(s) Terms and Conditions

Figure 1 Binding Affinities of the anti-hTfR Antibody-Fused hIDS for TfRs and Human hM6PR (A) Schematic representation of JR-141, an anti-hTfR antibody-fused hIDS used in this study. (B) Affinity of JR-141 for human and monkey TfRs and human M6PR. Affinity of naked hIDS for human M6PR is also shown (mean ± SD, n = 3). kon, association rate constant; koff, dissociation rate constant; KD, equilibrium dissociation constant. Molecular Therapy 2018 26, 1366-1374DOI: (10.1016/j.ymthe.2018.02.032) Copyright © 2018 The Author(s) Terms and Conditions

Figure 2 The Receptor-Mediated Incorporation into Fibroblasts (A) Concentration-dependent incorporation of JR-141 or naked hIDS into CCD-1076Sk human fibroblasts determined by electrochemiluminescent immunoassay using the anti-hIDS monoclonal antibodies. The incubation time was 20 hr. The values were normalized by the amount of total cellular protein (mean ± SD, n = 3). (B) Inhibition of JR-141 incorporation by M6P (10 mM) or the humanized anti-hTfR monoclonal antibody (400 μg/mL). The concentration of the drugs used in this experiment was 20 μg/mL. The calculated molecular weights (without sugar chains) of JR-141 and naked hIDS are 265,110.93 and 59,274.99, respectively. Molecular Therapy 2018 26, 1366-1374DOI: (10.1016/j.ymthe.2018.02.032) Copyright © 2018 The Author(s) Terms and Conditions

Figure 3 Distribution of JR-141 in TFRC-KI Mice after Intravenous Administration (A and B) Pharmacokinetics of JR-141 and naked hIDS in the plasma (A) and the brain homogenates (B). Either JR-141 or the naked enzyme was intravenously administered at a dose of 1 mg/kg. The concentrations of these recombinant proteins were determined by electrochemiluminescent immunoassay (mean ± SD, n = 3; *p < 0.05, ***p < 0.001, t test). Concentrations of the naked hIDS in the brain were incidentally detected at low level in only one animal 1 hr after administration. Statistical analysis was performed using the lower limit value of detection for other animals and other time points. See Table S1 for detailed pharmacokinetic parameters with moment analysis and Figure S2 for distribution of JR-141 and hIDS in peripheral tissues. (C) Immunohistochemical analysis in the brain of TFRC-KI mice 24 hr after intravenous injection of JR-141 or naked hIDS. Arrows indicate Purkinje cells. Scale bars, 20 μm. (D) In vivo imaging of the mice using IVIS Lumina III. Images were acquired at 24 hr after intravenous injection of JR-141 or hIDS. (E) Ex vivo imaging of resected brains after saline perfusion. Color bars indicate radiant efficiency ([p/s/cm2/sr]/[mW/cm2]). Molecular Therapy 2018 26, 1366-1374DOI: (10.1016/j.ymthe.2018.02.032) Copyright © 2018 The Author(s) Terms and Conditions

Figure 4 Distribution of JR-141 in Cynomolgus Monkeys after Intravenous Administration (A) Pharmacokinetics of JR-141 in the plasma of the monkey. JR-141 was administered intravenously at a dose of 5 mg/kg (0–8 hr, n = 4; 12 and 24 hr, n = 2). Data were plotted as mean ± SD. Detailed pharmacokinetic parameters are presented in Table S2. (B and C) Concentrations of JR-141 in the peripheral tissues (B) and the brain and spinal cord (C). The heart, kidney, liver, lung, spleen, cerebral cortex, cerebellum, hippocampus, and spinal cord were resected. JR-141 in each tissue homogenate was quantified by electrochemiluminescent immunoassay (n = 2). Bars indicate the mean. (D) Immunohistochemical analysis of the cerebellum. Arrows indicate Purkinje cells. (E) Immunohistochemical analysis of the hippocampus. Arrows indicate the pyramidal cells. The brains were resected at 8 hr after the administration. Scale bars, 20 μm. Molecular Therapy 2018 26, 1366-1374DOI: (10.1016/j.ymthe.2018.02.032) Copyright © 2018 The Author(s) Terms and Conditions

Figure 5 Reduction in Accumulation of GAGs by JR-141 in the Brain and the Peripheral Tissues of TFRC-KI/Ids-KO Double-Mutant Mice JR-141 was intravenously administered to the mice at a dose of 1, 3, or 10 mg/kg BW once a week for 4 weeks. GAGs were quantified 1 week after the final dosing in the resected brain, heart, kidney, liver, lung, and spleen. Values are expressed as % accumulation when mean GAG levels in the WT mice were considered to be 0% and those in Ids-KO mice were considered to be 100%. Bars indicate the mean for each group (n = 4). **p < 0.01 by Dunnett test (Ids-KO versus JR-141 groups) and ##p < 0.01 by Student’s t test (Ids-KO versus hIDS groups). N.S., not significant. The absolute values of the concentration and detailed statistical analysis between groups are presented in Table S3. Molecular Therapy 2018 26, 1366-1374DOI: (10.1016/j.ymthe.2018.02.032) Copyright © 2018 The Author(s) Terms and Conditions